

CLAIMS

1. The use of at least one immunogenic peptide representing a T epitope presented by MHC I,
5 chosen from:
 - a) a peptide comprising the sequence EX₁AGIGILX₂ (SEQ ID NO : 1) in which X₁ represents A or P, and X₂ represents T or Y, capable of inducing a cytotoxic response directed against the Melan-A
10 antigen;
 - b) a peptide comprising the sequence EVDPIGHVY (SEQ ID NO : 2), capable of inducing a cytotoxic T response directed against the MAGE-A6 antigen;
 - c) a peptide comprising the sequence VPLDCVLYR
15 (SEQ ID NO : 3), capable of inducing a cytotoxic response directed against the gp100 antigen;
 - d) a peptide comprising the sequence TPRLPSSADVEF (SEQ ID NO : 4), capable of inducing a cytotoxic response directed against the tyrosinase antigen;
 - e) a peptide comprising the sequence MPFATPMEA
20 (SEQ ID NO : 5), capable of inducing a cytotoxic response directed against the NY-ESO-1 antigen;for obtaining a medicinal product intended for antitumor immunotherapy in an HLA-B35 patient.
25
2. The use as claimed in claim 1, characterized in that said peptide is chosen from:
 - a) a peptide of sequence chosen from:
TAEAAAGIGILTV (SEQ ID NO : 6), EAAGIGILTVIL (SEQ
30 ID NO : 7), EAAGIGILTV (SEQ ID NO : 8), EAAGIGILTY (SEQ ID NO : 9), EAAGIGILY (SEQ ID NO:10), EPAGIGILTY (SEQ ID NO:11), EPAGIGILTV (SEQ ID NO : 12);
 - b) a peptide of sequence EVDPIGHVY (SEQ ID NO :
35 2);
 - c) a peptide of sequence chosen from VPLDCVLYR (SEQ ID NO : 3) and VPLDCVLYRY (SEQ ID NO : 13);

- d) a peptide of sequence chosen from
TPRLPSSADVEFCL (SEQ ID NO : 15) and TPRLPSSADVEF
(SEQ ID NO : 4);
- e) a peptide of sequence chosen from:
5 LAMPFATPMEAEL (SEQ ID NO : 16), LAMPFATPMEAE (SEQ
ID NO : 17), MPFATPMEAEL (SEQ ID NO : 18),
MPFATPMEAE (SEQ ID NO : 19) and MPFATPMEA (SEQ ID
NO : 5).
- 10 3. An immunogenic peptide representing a T epitope
presented by MHC I, chosen from:
- a peptide of sequence chosen from: EAAGIGILTY
(SEQ ID NO : 9), EAAGIGILY (SEQ ID NO : 10),
15 EPAGIGILTY (SEQ ID NO : 11), EPAGIGILTV (SEQ ID NO
: 12);
 - a peptide of sequence chosen from: VPLDCVLYR
(SEQ ID NO : 3), VPLDCVLYRY (SEQ ID NO : 13) and
PVPLDCVLYRY (SEQ ID NO : 14);
 - a peptide of sequence chosen from:
20 TPRLPSSADVERFCL (SEQ ID NO : 15) and TPRLPSSADVEF
(SEQ ID NO : 4).
4. A multiepitope composition comprising at least two
peptides of two different categories among the
25 categories (a), b), c), d) and e) as defined in
claim 1 or 2.
5. The multiepitope composition as claimed in claim
4, characterized in that it comprises at least one
30 peptide from each of these categories a), b), c),
d) and e) as defined in claim 1 or 2.
6. The multiepitope composition as claimed in either
one of claims 4 and 5, characterized in that it
35 consists of a chimeric polypeptide comprising one
or more copies of each of said peptides.
7. A polynucleotide encoding a chimeric polypeptide
as claimed in claim 6.

8. An antigen-presenting cell expressing an MHC I HLA-B35 allele, characterized in that it is loaded with a peptide as defined in either one of claims 1 and 2.
5
9. An antigen-presenting cell expressing an MHC I HLA-B35 allele, characterized in that it is transfected with a polynucleotide as claimed in claim 7.
10
10. The use of at least one peptide as defined in any one of claims 1 to 3, for detecting *in vitro*, CTLs directed against one or more of the antigens Melan-A, MAGE-A6, gp100, tyrosinase and NY-ESO-1, in a biological sample obtained from an HLA-B35 individual.
15